Healthcare
Live Price
Offline$2.68
-3.25% today
1Y Change
+8.85%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sana Biotechnology, Inc. (SANA) is a Healthcare stock with a market cap of $910.00M and listed on NASDAQ. The stock last traded around $2.68 and up 8.8% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.2%, free cash flow +43.6% with operating margin 0.0% and ROIC -70.9%. Stock Foundry combines SANA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SANA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SANA Max Drawdown
-54.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SANA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$355.9M
-32.1% YoY
Free Cash Flow
-$280.9M
+9.7% YoY
Revenue Growth
+0.0%
EPS Growth
+17.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -13M | 0 | 0 | 0 | 0 |
| Operating Income | -191M | -273M | -293M | -273M | -357M |
| EBITDA | -178M | -255M | -269M | -257M | -346M |
| Net Income | -244M | -267M | -283M | -269M | -356M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 72M | 128M | 134M | 177M | 253M |
| Total Assets | 417M | 501M | 565M | 823M | 1.1B |
| Total Liabilities | 256M | 251M | 278M | 323M | 401M |
| Shareholder Equity | 161M | 251M | 288M | 499M | 729M |
| Total Debt | 79M | 94M | 104M | 108M | 111M |
| Net Debt | 7M | -33M | -29M | -69M | -142M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
251M
+13.4% YoY
Capital Expenditures
30M
-43.0% YoY
Free Cash Flow
281M
+9.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-142.0%
Debt / Equity
0.49x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.